<DOC>
	<DOCNO>NCT00099606</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics , effect food , continue exploratory research BMS-354825 patient solid tumor respond standard treatment , effective standard treatment exists .</brief_summary>
	<brief_title>Phase I ( PH I ) Mad Refractory Solid Tumor Study</brief_title>
	<detailed_description />
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Signed write informed consent Available protocolrequired followup ECOG performance status score 0 1 ( See Appendix 1 ) Histologic cytologic diagnosis primary solid ( i.e. , nonhematologic ) malignancy Evidence ( radiographic tissue confirmation ) disease metastatic Metastatic disease progress follow currently available standard therapy standard therapy exists . ( Prior adjuvant neoadjuvant therapy permit . Prior investigational agent permit ) ; Measurable nonmeasurable disease define Section 3.3.2.1 Adequate bone marrow function define : absolute neutrophil count ( neutrophil band ) &gt; =2,000 cells/mm3 platelet count &gt; =125,000 cells/mm3 hemoglobin &gt; =9.0 g/dl Adequate hepatic function define : total bilirubin &lt; =1.5 time institutional upper limit normal , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; =2.0 time institutional upper limit normal Adequate renal function define : serum creatinine &lt; =1.5 time institutional upper normal limit Serum potassium magnesium level within institutional normal limit . Total serum calcium ionized calcium level must great equal low limit normal . Patients low potassium magnesium level may replete allow protocol entry . CD4+ Tcell count &gt; =the institutional low limit normal . Prior chemo , radio , hormonal immunotherapy allow . Patients must recover toxicity due prior therapy i.e. , toxicity resolve baseline deem irreversible . At least 4 week must elapse since last chemotherapy ( 6 week nitrosoureas , mitomycinC , liposomal doxorubicin ) , immunotherapy radiotherapy begin protocol therapy . At least 2 week must elapse since last hormonal therapy exposure `` target '' kinase inhibitor ( e.g. , imatinib mesylate ) . Bleeding time &lt; =upper limit institutional normal platelet aggregometry result within institutional normal limit Men woman , age 18 older . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study period least 1 month prior least 3 month study manner risk pregnancy minimize . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal [ define amenorrhea &gt; =12 consecutive month ; woman hormone replacement therapy ( HRT ) document serum follicle stimulate hormone ( FSH ) level &gt; 35 mIU/mL ] . Even woman use oral , implanted injectable contraceptive hormone mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy practice abstinence partner sterile ( e.g. , vasectomy ) , consider child bear potential . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour prior start study medication . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period include period one month prior start study medication period least 3 month study . WOCBP use prohibit contraceptive method . Women pregnant breastfeeding . Women positive pregnancy test enrollment prior study drug administration . Men unwilling unable use acceptable method birth control entire study period least 3 month completion study medication sexual partner WOCBP . Received extensive prior radiation therapy bone marrow . Generally , patient radiation &lt; =25 % bone marrowcontaining skeleton ( see Appendix 2 ) . Known brain metastasis . Patients symptoms brain metastasis eligible unless brain metastasis rule CT MRI . A serious uncontrolled medical disorder active infection would impair ability patient receive protocol therapy . Uncontrolled significant cardiovascular disease , include : A myocardial infarction within 12 month Uncontrolled angina within 6 month Congestive heart failure within 6 month Diagnosed suspected congenital long QT syndrome Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , torsade de pointes ) . Any patient history arrhythmia discuss BMS Medical Monitor prior entry study . Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) Any history second third degree heart block ( may eligible currently pacemaker ) Heart rate &lt; 50 / minute preentry electrocardiogram Uncontrolled hypertension . Dementia alter mental status would prohibit understanding rendering informed consent ; History significant bleeding disorder include : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) Documented major bleed episode GI tract within 6 month unless long significant risk due surgical intervention Vasculitis . Received investigational agent within 4 week prior start protocol therapy . Patients currently take drug generally accept risk cause Torsades de Pointes include : Class IA antiarrhythmic agent ( quinidine , procainamide , disopyramide , mexiletine ) Class III antiarrhythmic agent ( amiodarone , sotalol , ibutilide , dofetilide ) Macrolide antibiotic ( erythromycin , clarithromycin ) Antipsychotics ( chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide ) Tricyclic antidepressants Miscellaneous ( cisapride , bepridil , inapsine , methadone , arsenic ) . Patients discontinued medication must washout period least 5 day least 5 halflives drug ( whichever great ) prior first dose BMS354825 . Patients take medication inhibit platelet function ( e.g. , aspirin , dipyridamole , epoprostenol , eptifibatide , clopidogrel , cilostazol , abciximab , ticlopidine , nonsteroidal antiinflammatory drug ) anticoagulant ( warfarin , heparin/low molecular weight heparin [ e.g. , danaparoid , dalteparin , tinzaparin , enoxaparin ] ) . Patients discontinued aspirin must washout period least 7 day lowdose aspirin ( &lt; =325 mg/day ) 14 day higherdose aspirin ( &gt; 325 mg/day ) prior first dose BMS354825 . Patients discontinue antiplatelet anticoagulant medication must washout period least 5 day least 5 half life drug ( whichever great ) prior first dose BMS354825 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>